<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26828013</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>07</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>31</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-7980</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>380</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Sep</Month>
              <Day>28</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer letters</Title>
          <ISOAbbreviation>Cancer Lett</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Regulation of prostate cancer progression by the tumor microenvironment.</ArticleTitle>
        <Pagination>
          <StartPage>340</StartPage>
          <EndPage>348</EndPage>
          <MedlinePgn>340-8</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2015.12.022</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0304-3835(15)00773-9</ELocationID>
        <Abstract>
          <AbstractText>Prostate cancer remains the most frequently diagnosed cancer in men in North America, and despite recent advances in treatment patients with metastatic disease continue to have poor five-year survival rates. Recent studies in prostate cancer have revealed the critical role of the tumor microenvironment in the initiation and progression to advanced disease. Experimental data have uncovered a reciprocal relationship between the cells in the microenvironment and malignant tumor cells in which early changes in normal tissue microenvironment can promote tumorigenesis and in turn tumor cells can promote further pro-tumor changes in the microenvironment. In the tumor microenvironment, the presence of persistent immune infiltrates contributes to the recruitment and reprogramming of other non-immune stromal cells including cancer-associated fibroblasts and a unique recently identified population of metastasis-initiating cells (MICs). These MICs, which can also be found as part of the circulating tumor cell (CTC) population in PC patients, promote cancer cell transformation, enhance metastatic potential and confer therapeutic resistance. MICs act can on other cells within the tumor microenvironment in part by secreting exosomes that reprogram adjacent stromal cells to create a more favorable tumor microenvironment to support continued cancer growth and progression. We review here the current data on the intricate relationship between inflammation, reactive stroma, tumor cells and disease progression in prostate cancer.</AbstractText>
          <CopyrightInformation>Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Shiao</LastName>
            <ForeName>Stephen L</ForeName>
            <Initials>SL</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Radiation Oncology and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. Electronic address: stephen.shiao@cshs.org.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chu</LastName>
            <ForeName>Gina Chia-Yi</ForeName>
            <Initials>GC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. Electronic address: chia-yi.chu@cshs.org.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chung</LastName>
            <ForeName>Leland W K</ForeName>
            <Initials>LW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>K08 CA191139</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2016</Year>
          <Month>01</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cancer Lett</MedlineTA>
        <NlmUniqueID>7600053</NlmUniqueID>
        <ISSNLinking>0304-3835</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002450" MajorTopicYN="N">Cell Communication</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="Y">Cell Movement</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D065150" MajorTopicYN="N">Cellular Reprogramming</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009360" MajorTopicYN="N">Neoplastic Cells, Circulating</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017154" MajorTopicYN="N">Stromal Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="Y">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Exosomes</Keyword>
        <Keyword MajorTopicYN="Y">Metastasis</Keyword>
        <Keyword MajorTopicYN="Y">Metastasis-initiating cells</Keyword>
        <Keyword MajorTopicYN="Y">Prostate cancer</Keyword>
        <Keyword MajorTopicYN="Y">Tumor immune microenvironment</Keyword>
        <Keyword MajorTopicYN="Y">microRNA</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2015</Year>
          <Month>10</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2015</Year>
          <Month>12</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2015</Year>
          <Month>12</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>2</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>2</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>7</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26828013</ArticleId>
        <ArticleId IdType="mid">NIHMS760733</ArticleId>
        <ArticleId IdType="pmc">PMC5317350</ArticleId>
        <ArticleId IdType="doi">10.1016/j.canlet.2015.12.022</ArticleId>
        <ArticleId IdType="pii">S0304-3835(15)00773-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Shukla ME, Yu C, Reddy CA, Stephans KL, Klein EA, Abdel-Wahab M, Ciezki J, Tendulkar RD. Evaluation of the current prostate cancer staging system based on cancer-specific mortality in the surveillance epidemiology and end results database. Clin Genitourin Cancer. 2015;13:17–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25571871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics 2014, CA: a cancer journal for clinicians. 2014;64:9–29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24399786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7:256–269.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3552388</ArticleId>
            <ArticleId IdType="pubmed">17384581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taverna G, Pedretti E, Di Caro G, Borroni EM, Marchesi F, Grizzi F. Inflammation and prostate cancer: friends or foe? Inflammation research : official journal of the European Histamine Research Society … [et al.] 2015;64:275–286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25788425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21376230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ayala G, Tuxhorn JA, Wheeler TM, Frolov A, Scardino PT, Ohori M, Wheeler M, Spitler J, Rowley DR. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res. 2003;9:4792–4801.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14581350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tuxhorn JA, Ayala GE, Rowley DR. Reactive stroma in prostate cancer progression. J Urol. 2001;166:2472–2483.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11696814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res. 2007;67:10123–10128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17974953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Placencio VR, Li X, Sherrill TP, Fritz G, Bhowmick NA. Bone marrow derived mesenchymal stem cells incorporate into the prostate during regrowth. PLoS One. 2010;5:e12920.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2944821</ArticleId>
            <ArticleId IdType="pubmed">20886110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dakhova O, Ozen M, Creighton CJ, Li R, Ayala G, Rowley D, Ittmann M. Global gene expression analysis of reactive stroma in prostate cancer. Clin Cancer Res. 2009;15:3979–3989.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2734921</ArticleId>
            <ArticleId IdType="pubmed">19509179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sung SY, Hsieh CL, Law A, Zhau HE, Pathak S, Multani AS, Lim S, Coleman IM, Wu LC, Figg WD, Dahut WL, Nelson P, Lee JK, Amin MB, Lyles R, Johnstone PA, Marshall FF, Chung LW. Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Res. 2008;68:9996–10003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3105756</ArticleId>
            <ArticleId IdType="pubmed">19047182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayward SW, Wang Y, Cao M, Hom YK, Zhang B, Grossfeld GD, Sudilovsky D, Cunha GR. Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res. 2001;61:8135–8142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11719442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rhee HW, Zhau HE, Pathak S, Multani AS, Pennanen S, Visakorpi T, Chung LW. Permanent phenotypic and genotypic changes of prostate cancer cells cultured in a three-dimensional rotating-wall vessel. In Vitro Cell Dev Biol Anim. 2001;37:127–140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11370803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pathak S, Nemeth MA, Multani AS, Thalmann GN, von Eschenbach AC, Chung LW. Can cancer cells transform normal host cells into malignant cells? British journal of cancer. 1997;76:1134–1138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2228111</ArticleId>
            <ArticleId IdType="pubmed">9365160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999;59:5002–5011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3300837</ArticleId>
            <ArticleId IdType="pubmed">10519415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harper J, Sainson RC. Regulation of the anti-tumour immune response by cancer-associated fibroblasts. Seminars in cancer biology. 2014;25:69–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24406209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bruzzese F, Hagglof C, Leone A, Sjoberg E, Roca MS, Kiflemariam S, Sjoblom T, Hammarsten P, Egevad L, Bergh A, Ostman A, Budillon A, Augsten M. Local and systemic protumorigenic effects of cancer-associated fibroblast-derived GDF15. Cancer Res. 2014;74:3408–3417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24780757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG, Moses HL. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science. 2004;303:848–851.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14764882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>S ELA, Mager I, Breakefield XO, Wood MJ. Extracellular vesicles: biology and emerging therapeutic opportunities. Nature reviews. Drug discovery. 2013;12:347–357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23584393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Josson S, Gururajan M, Sung SY, Hu P, Shao C, Zhau HE, Liu C, Lichterman J, Duan P, Li Q, Rogatko A, Posadas EM, Haga CL, Chung LW. Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis. Oncogene. 2015;34:2690–2699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25065597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Josson S, Gururajan M, Hu P, Shao C, Chu GY, Zhau HE, Liu C, Lao K, Lu CL, Lu YT, Lichterman J, Nandana S, Li Q, Rogatko A, Berel D, Posadas EM, Fazli L, Sareen D, Chung LW. miR-409-3p/-5p promotes tumorigenesis epithelial-to-mesenchymal transition and bone metastasis of human prostate cancer. Clin Cancer Res. 2014;20:4636–4646.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4155061</ArticleId>
            <ArticleId IdType="pubmed">24963047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gururajan M, Josson S, Chu GC, Lu CL, Lu YT, Haga CL, Zhau HE, Liu C, Lichterman J, Duan P, Posadas EM, Chung LW. miR-154* and miR-379 in the DLK1-DIO3 microRNA mega-cluster regulate epithelial to mesenchymal transition and bone metastasis of prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014;20:6559–6569.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4710473</ArticleId>
            <ArticleId IdType="pubmed">25324143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barron DA, Rowley DR. The reactive stroma microenvironment and prostate cancer progression. Endocrine-related cancer. 2012;19:R187–R204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3716392</ArticleId>
            <ArticleId IdType="pubmed">22930558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong YN, Ferraldeschi R, Attard G, de Bono J. Evolution of androgen receptor targeted therapy for advanced prostate cancer. Nature reviews. Clinical oncology. 2014;11:365–376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24840076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21:309–322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22439926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23890059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woo SR, Corrales L, Gajewski TF. Innate immune recognition of cancer. Annual review of immunology. 2015;33:445–474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25622193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348:69–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25838375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015;27:462–472.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4400235</ArticleId>
            <ArticleId IdType="pubmed">25858805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chittezhath M, Dhillon MK, Lim JY, Laoui D, Shalova IN, Teo YL, Chen J, Kamaraj R, Raman L, Lum J, Thamboo TP, Chiong E, Zolezzi F, Yang H, Van Ginderachter JA, Poidinger M, Wong AS, Biswas SK. Molecular profiling reveals a tumor-promoting phenotype of monocytes and macrophages in human cancer progression. Immunity. 2014;41:815–829.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25453823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen W, Konkel JE. Development of thymic Foxp3(+) regulatory T cells: TGF-beta matters. European journal of immunology. 2015;45:958–965.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4428761</ArticleId>
            <ArticleId IdType="pubmed">25684698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hussein MR, Al-Assiri M, Musalam AO. Phenotypic characterization of the infiltrating immune cells in normal prostate benign nodular prostatic hyperplasia and prostatic adenocarcinoma. Experimental and molecular pathology. 2009;86:108–113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19111537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gurel B, Lucia MS, Thompson IM, Jr, Goodman PJ, Tangen CM, Kristal AR, Parnes HL, Hoque A, Lippman SM, Sutcliffe S, Peskoe SB, Drake CG, Nelson WG, De Marzo AM, Platz EA. Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial Cancer epidemiology biomarkers &amp; prevention : a publication of the American Association for Cancer Research. cosponsored by the American Society of Preventive Oncology. 2014;23:847–856.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4012292</ArticleId>
            <ArticleId IdType="pubmed">24748218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Visser KE, Eichten A, M L. Coussens, Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006;6:24–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16397525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crusz SM, Balkwill FR. Inflammation and cancer: advances and new agents. Nature reviews. Clinical oncology. 2015</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26122183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pateras IS, Havaki S, Nikitopoulou X, Vougas K, Townsend PA, Panayiotidis MI, Georgakilas AG, Gorgoulis VG. The DNA damage response and immune signaling alliance: Is it good or bad? Nature decides when and where Pharmacology &amp; therapeutics. 2015;154:36–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26145166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schroder F, Sciarra A, Tubaro A. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. European urology. 2011;60:106–117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21497433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, Thompson TC. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res. 2000;60:5857–5861.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11059783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nonomura N, Takayama H, Nakayama M, Nakai Y, Kawashima A, Mukai M, Nagahara A, Aozasa K, Tsujimura A. Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer. BJU international. 2011;107:1918–1922.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21044246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lanciotti M, Masieri L, Raspollini MR, Minervini A, Mari A, Comito G, Giannoni E, Carini M, Chiarugi P, Serni S. The role of M1 and M2 macrophages in prostate cancer in relation to extracapsular tumor extension and biochemical recurrence after radical prostatectomy. BioMed research international. 2014;2014:486798.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3967497</ArticleId>
            <ArticleId IdType="pubmed">24738060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujii T, Shimada K, Asai O, Tanaka N, Fujimoto K, Hirao K, Konishi N. Immunohistochemical analysis of inflammatory cells in benign and precancerous lesions and carcinoma of the prostate Pathobiology : journal of immunopathology. molecular and cellular biology. 2013;80:119–126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23328608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Comito G, Giannoni E, Segura CP, Barcellos-de-Souza P, Raspollini MR, Baroni G, Lanciotti M, Serni S, Chiarugi P. Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression. Oncogene. 2014;33:2423–2431.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23728338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Escamilla J, Schokrpur S, Liu C, Priceman SJ, Moughon D, Jiang Z, Pouliot F, Magyar C, Sung JL, Xu J, Deng G, West BL, Bollag G, Fradet Y, Lacombe L, Jung ME, Huang J, Wu L. CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy. Cancer Res. 2015;75:950–962.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4359956</ArticleId>
            <ArticleId IdType="pubmed">25736687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu J, Escamilla J, Mok S, David J, Priceman S, West B, Bollag G, McBride W, Wu L. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res. 2013;73:2782–2794.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4097014</ArticleId>
            <ArticleId IdType="pubmed">23418320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahon KL, Lin HM, Castillo L, Lee BY, Lee-Ng M, Chatfield MD, Chiam K, Breit SN, Brown DA, Molloy MP, Marx GM, Pavlakis N, Boyer MJ, Stockler MR, Daly RJ, Henshall SM, Horvath LG. Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer. British journal of cancer. 2015;112:1340–1348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4402456</ArticleId>
            <ArticleId IdType="pubmed">25867259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu G, Lu S, Wang X, Page ST, Higano CS, Plymate SR, Greenberg NM, Sun S, Li Z, Wu JD. Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis. The Journal of clinical investigation. 2013;123:4410–4422.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3784540</ArticleId>
            <ArticleId IdType="pubmed">24018560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gannon PO, Poisson AO, Delvoye N, Lapointe R, Mes-Masson AM, Saad F. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. Journal of immunological methods. 2009;348:9–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19552894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pasero C, Gravis G, Granjeaud S, Guerin M, Thomassin-Piana J, Rocchi P, Salem N, Walz J, Moretta A, Olive D. Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer. Oncotarget. 2015;6:14360–14373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4546472</ArticleId>
            <ArticleId IdType="pubmed">25961317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johansson A, Rudolfsson S, Hammarsten P, Halin S, Pietras K, Jones J, Stattin P, Egevad L, Granfors T, Wikstrom P, Bergh A. Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. The American journal of pathology. 2010;177:1031–1041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2913352</ArticleId>
            <ArticleId IdType="pubmed">20616342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fleischmann A, Schlomm T, Kollermann J, Sekulic N, Huland H, Mirlacher M, Sauter G, Simon R, Erbersdobler A. Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis. The Prostate. 2009;69:976–981.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19274666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittoni P, Tripodo C, Piconese S, Mauri G, Parenza M, Rigoni A, Sangaletti S, Colombo MP. Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. Cancer Res. 2011;71:5987–5997.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21896641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Templeton AJ, Pezaro C, Omlin A, McNamara MG, Leibowitz-Amit R, Vera-Badillo FE, Attard G, de Bono JS, Tannock IF, Amir E. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer. 2014;120:3346–3352.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24995769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nuhn P, Vaghasia AM, Goyal J, Zhou XC, Carducci MA, Eisenberger MA, Antonarakis ES. Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel. BJU international. 2014;114:E11–E17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4004702</ArticleId>
            <ArticleId IdType="pubmed">24529213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang LY, Izumi K, Lai KP, Liang L, Li L, Miyamoto H, Lin WJ, Chang C. Infiltrating macrophages promote prostate tumorigenesis via modulating androgen receptor-mediated CCL4-STAT3 signaling. Cancer Res. 2013;73:5633–5646.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3833080</ArticleId>
            <ArticleId IdType="pubmed">23878190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okada K, Kojima M, Naya Y, Kamoi K, Yokoyama K, Takamatsu T, Miki T. Correlation of histological inflammation in needle biopsy specimens with serum prostate-specific antigen levels in men with negative biopsy for prostate cancer. Urology. 2000;55:892–898.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10840104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittoni P, Colombo MP. The dark side of mast cell-targeted therapy in prostate cancer. Cancer Res. 2012;72:831–835.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22307838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taverna G, Giusti G, Seveso M, Hurle R, Colombo P, Stifter S, Grizzi F. Mast cells as a potential prognostic marker in prostate cancer. Disease markers. 2013;35:711–720.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3844173</ArticleId>
            <ArticleId IdType="pubmed">24324287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frankel TL, Burns W, Riley J, Morgan RA, Davis JL, Hanada K, Quezado M, Rosenberg SA, Royal RE. Identification and characterization of a tumor infiltrating CD56(+)/CD16 (−) NK cell subset with specificity for pancreatic and prostate cancer cell lines. Cancer immunology, immunotherapy : CII. 2010;59:1757–1769.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6369534</ArticleId>
            <ArticleId IdType="pubmed">20734041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwek SS, Lewis J, Zhang L, Weinberg V, Greaney SK, Harzstark AL, Lin AM, Ryan CJ, Small EJ, Fong L. Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab. Cancer Immunol Res. 2015</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4561203</ArticleId>
            <ArticleId IdType="pubmed">25968455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McArdle PA, Canna K, McMillan DC, McNicol AM, Campbell R, Underwood MA. The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. British journal of cancer. 2004;91:541–543.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2409839</ArticleId>
            <ArticleId IdType="pubmed">15266325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ness N, Andersen S, Valkov A, Nordby Y, Donnem T, Al-Saad S, Busund LT, Bremnes RM, Richardsen E. Infiltration of CD8+ lymphocytes is an independent prognostic factor of biochemical failure-free survival in prostate cancer. The Prostate. 2014;74:1452–1461.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25111810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Saeter T, Vlatkovic L, Servoll E, Waaler G, Axcrona U, Giercksky KE, Nesland JM, Suo ZH, Axcrona K. Dendritic and lymphocytic cell infiltration in prostate carcinoma. Histology and histopathology. 2013;28:1621–1628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23729368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davidsson S, Ohlson AL, Andersson SO, Fall K, Meisner A, Fiorentino M, Andren O, Rider JR. CD4 helper T cells CD8 cytotoxic T cells, and FOXP3(+) regulatory Tcells with respect to lethal prostate cancer Modern pathology : an official journal of the United States and Canadian Academy of Pathology. Inc. 2013;26:448–455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23041830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ebelt K, Babaryka G, Frankenberger B, Stief CG, Eisenmenger W, Kirchner T, Schendel DJ, Noessner E. Prostate cancer lesions are surrounded by FOXP3+ PD-1+ and B7-H1+ lymphocyte clusters. European journal of cancer. 2009;45:1664–1672.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19318244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller AM, Lundberg K, Ozenci V, Banham AH, Hellstrom M, Egevad L, Pisa P. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. Journal of immunology. 2006;177:7398–7405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17082659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Idorn M, Kollgaard T, Kongsted P, Sengelov L, Thor Straten P. Correlation between frequencies of blood monocytic myeloid-derived suppressor cells regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer Cancer immunology. immunotherapy : CII. 2014;63:1177–1187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25085000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jochems C, Tucker JA, Tsang KY, Madan RA, Dahut WL, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates Cancer immunology. immunotherapy : CII. 2014;63:407–418.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6314199</ArticleId>
            <ArticleId IdType="pubmed">24514956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andreu P, Johansson M, Affara NI, Pucci F, Tan T, Junankar S, Korets L, Lam J, Tawfik D, DeNardo DG, Naldini L, de Visser KE, De Palma M, Coussens LM. FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell. 2010;17:121–134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3082507</ArticleId>
            <ArticleId IdType="pubmed">20138013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Affara NI, Ruffell B, Medler TR, Gunderson AJ, Johansson M, Bornstein S, Bergsland E, Steinhoff M, Li Y, Gong Q, Ma Y, Wiesen JF, Wong MH, Kulesz-Martin M, Irving B, Coussens LM. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. Cancer Cell. 2014;25:809–821.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4063283</ArticleId>
            <ArticleId IdType="pubmed">24909985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woo JR, Liss MA, Muldong MT, Palazzi K, Strasner A, Ammirante M, Varki N, Shabaik A, Howell S, Kane CJ, Karin M, Jamieson CA. Tumor infiltrating B-cells are increased in prostate cancer tissue. Journal of translational medicine. 2014;12:30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3914187</ArticleId>
            <ArticleId IdType="pubmed">24475900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strasner A, Karin M. Immune Infiltration and Prostate Cancer. Frontiers in oncology. 2015;5:128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4495337</ArticleId>
            <ArticleId IdType="pubmed">26217583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ammirante M, Kuraishy AI, Shalapour S, Strasner A, Ramirez-Sanchez C, Zhang W, Shabaik A, Karin M. An IKKalpha-E2F1-BMI1 cascade activated by infiltrating B cells controls prostate regeneration and tumor recurrence. Genes &amp; development. 2013;27:1435–1440.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3713424</ArticleId>
            <ArticleId IdType="pubmed">23796898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shalapour S, Font-Burgada J, Di Caro G, Zhong Z, Sanchez-Lopez E, Dhar D, Willimsky G, Ammirante M, Strasner A, Hansel DE, Jamieson C, Kane CJ, Klatte T, Birner P, Kenner L, Karin M. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature. 2015;521:94–98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4501632</ArticleId>
            <ArticleId IdType="pubmed">25924065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pantel K, Speicher MR. The biology of circulating tumor cells. Oncogene. 2015</Citation>
        </Reference>
        <Reference>
          <Citation>De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13:97–110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23344542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyamoto DT, Sequist LV, Lee RJ. Circulating tumour cells-monitoring treatment response in prostate cancer. Nature reviews. Clinical oncology. 2014;11:401–412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24821215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chu GC, Chung LW. RANK-mediated signaling network and cancer metastasis. Cancer Metastasis Rev. 2014;33:497–509.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4087108</ArticleId>
            <ArticleId IdType="pubmed">24398859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chu GC, Zhau HE, Wang R, Rogatko A, Feng X, Zayzafoon M, Liu Y, Farach-Carson MC, You S, Kim J, Freeman MR, Chung LW. RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization. Endocrine-related cancer. 2014;21:311–326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3959765</ArticleId>
            <ArticleId IdType="pubmed">24478054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chu GC, Wang R, Zhau HE, Posadas E, Chung LW. Metastasis-initiating cells (MICs) as predictors of lethal progression of human prostate cancer. Prostate Cancer Fundation Research Retreats. 2014</Citation>
        </Reference>
        <Reference>
          <Citation>Hou JM, Krebs M, Ward T, Sloane R, Priest L, Hughes A, Clack G, Ranson M, Blackhall F, Dive C. Circulating tumor cells as a window on metastasis biology in lung cancer. The American journal of pathology. 2011;178:989–996.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3069884</ArticleId>
            <ArticleId IdType="pubmed">21356352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krebs MG, Metcalf RL, Carter L, Brady G, Blackhall FH, Dive C. Molecular analysis of circulating tumour cells-biology and biomarkers. Nature reviews. Clinical oncology. 2014;11:129–144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24445517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, Priest LJ, Greystoke A, Zhou C, Morris K, Ward T, Blackhall FH, Dive C. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol. 2012;30:525–532.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22253462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L, Massague J. Tumor self-seeding by circulating cancer cells. Cell. 2009;139:1315–1326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2810531</ArticleId>
            <ArticleId IdType="pubmed">20064377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ziaee S, Chu GC, Huang J, Sieh S, Chung LW. Prostate cancer metastasis: roles of recruitment reprogramming cell signal network and three-dimensional growth characteristics. Translational Andrology and Urology. 2015</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4708593</ArticleId>
            <ArticleId IdType="pubmed">26816842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chu GC, Wang R, Zhau HE, Posadas E, Chung LW. Metastasis-initiating cells (MICs) of circulating tumor cells (CTCs) as predictors of lethal progression of human prostate cancer. 6th Annual SOCCI Research Day. 2015</Citation>
        </Reference>
        <Reference>
          <Citation>Zhau HY, Chang SM, Chen BQ, Wang Y, Zhang H, Kao C, Sang QA, Pathak SJ, Chung LW. Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci U S A. 1996;93:15152–15157.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC26372</ArticleId>
            <ArticleId IdType="pubmed">8986779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chung LW, Zhau HE, Wu TT. Development of human prostate cancer models for chemoprevention and experimental therapeutics studies. J Cell Biochem Suppl. 1997;28–29:174–181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9589364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhau HE, Odero-Marah V, Lue HW, Nomura T, Wang R, Chu G, Liu ZR, Zhou BP, Huang WC, Chung LW. Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model. Clin Exp Metastasis. 2008;25:601–610.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3050737</ArticleId>
            <ArticleId IdType="pubmed">18535913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Christman JK. 5-Azacytidine and 5-aza-2’-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002;21:5483–5495.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12154409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, Escara-Wilke J, Wilder-Romans K, Dhanireddy S, Engelke C, Iyer MK, Jing X, Wu YM, Cao X, Qin ZS, Wang S, Feng FY, Chinnaiyan AM. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature. 2014;510:278–282.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4075966</ArticleId>
            <ArticleId IdType="pubmed">24759320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henssen A, Thor T, Odersky A, Heukamp L, El-Hindy N, Beckers A, Speleman F, Althoff K, Schafers S, Schramm A, Sure U, Fleischhack G, Eggert A, Schulte JH. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. Oncotarget. 2013;4:2080–2095.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3875771</ArticleId>
            <ArticleId IdType="pubmed">24231268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, Nekritz EA, Zeid R, Gustafson WC, Greninger P, Garnett MJ, McDermott U, Benes CH, Kung AL, Weiss WA, Bradner JE, Stegmaier K. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013;3:308–323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3672953</ArticleId>
            <ArticleId IdType="pubmed">23430699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, Mitsiades CS. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146:904–917.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3187920</ArticleId>
            <ArticleId IdType="pubmed">21889194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Myatt SS, Lam EW. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 2007;7:847–859.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17943136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teh MT, Gemenetzidis E, Patel D, Tariq R, Nadir A, Bahta AW, Waseem A, Hutchison IL. FOXM1 induces a global methylation signature that mimics the cancer epigenome in head and neck squamous cell carcinoma. PLoS One. 2012;7:e34329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3312909</ArticleId>
            <ArticleId IdType="pubmed">22461910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hwang S, Mahadevan S, Qadir F, Hutchison IL, Costea DE, Neppelberg E, Liavaag PG, Waseem A, Teh MT. Identification of FOXM1-induced epigenetic markers for head and neck squamous cell carcinomas. Cancer. 2013;119:4249–4258.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24114764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gemenetzidis E, Elena-Costea D, Parkinson EK, Waseem A, Wan H, Teh MT. Induction of human epithelial stem/progenitor expansion by FOXM1. Cancer Res. 2010;70:9515–9526.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3044465</ArticleId>
            <ArticleId IdType="pubmed">21062979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Radhakrishnan SK, Bhat UG, Hughes DE, Wang IC, Costa RH, Gartel AL. Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Res. 2006;66:9731–9735.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17018632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bang C, Thum T. Exosomes: new players in cell-cell communication. The international journal of biochemistry &amp; cell biology. 2012;44:2060–2064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22903023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Camussi G, Deregibus MC, Bruno S, Cantaluppi V, Biancone L. Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int. 2010;78:838–848.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20703216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cocucci E, Racchetti G, Meldolesi J. Shedding microvesicles: artefacts no more. Trends Cell Biol. 2009;19:43–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19144520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morello M, Minciacchi VR, de Candia P, Yang J, Posadas E, Kim H, Griffiths D, Bhowmick N, Chung LW, Gandellini P, Freeman MR, Demichelis F, Di Vizio D. Large oncosomes mediate intercellular transfer of functional microRNA. Cell Cycle. 2013;12:3526–3536.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3906338</ArticleId>
            <ArticleId IdType="pubmed">24091630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Vizio D, Kim J, Hager MH, Morello M, Yang W, Lafargue CJ, True LD, Rubin MA, Adam RM, Beroukhim R, Demichelis F, Freeman MR. Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res. 2009;69:5601–5609.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2853876</ArticleId>
            <ArticleId IdType="pubmed">19549916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hager MH, Morley S, Bielenberg DR, Gao S, Morello M, Holcomb IN, Liu W, Mouneimne G, Demichelis F, Kim J, Solomon KR, Adam RM, Isaacs WB, Higgs HN, Vessella RL, Di Vizio D, Freeman MR. DIAPH3 governs the cellular transition to the amoeboid tumour phenotype. EMBO Mol Med. 2012;4:743–760.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3494074</ArticleId>
            <ArticleId IdType="pubmed">22593025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Record M, Carayon K, Poirot M, Silvente-Poirot S. Exosomes as new vesicular lipid transporters involved in cell-cell communication and various pathophysiologies. Biochim Biophys Acta. 2014;1841:108–120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24140720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A, Ratajczak MZ. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia. 2006;20:1487–1495.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16791265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vishnubhatla I, Corteling R, Stevanato L, Hicks C, Sinden J. The development of stem cell-derived exosomes as a cell-free regenerative medicine. Journal of Circulating Biomarkers. 2014;3:1–14.</Citation>
        </Reference>
        <Reference>
          <Citation>Thery C, Boussac M, Veron P, Ricciardi-Castagnoli P, Raposo G, Garin J, Amigorena S. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. Journal of immunology. 2001;166:7309–7318.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11390481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janowska-Wieczorek A, Majka M, Kijowski J, Baj-Krzyworzeka M, Reca R, Turner AR, Ratajczak J, Emerson SG, Kowalska MA, Ratajczak MZ. Platelet-derived microparticles bind to hematopoietic stem/progenitor cells and enhance their engraftment. Blood. 2001;98:3143–3149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11698303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baj-Krzyworzeka M, Szatanek R, Weglarczyk K, Baran J, Urbanowicz B, Branski P, Ratajczak MZ, Zembala M. Tumour-derived microvesicles carry several surface determinants mRNA of tumour cells and transfer some of these determinants to monocytes. Cancer immunology, immunotherapy : CII. 2006;55:808–818.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16283305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ratajczak J, Miekus K, Kucia M, Zhang J, Reca R, Dvorak P, Ratajczak MZ. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia. 2006;20:847–856.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16453000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9:654–659.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17486113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim HS, Choi DY, Yun SJ, Choi SM, Kang JW, Jung JW, Hwang D, Kim KP, Kim DW. Proteomic analysis of microvesicles derived from human mesenchymal stem cells. J Proteome Res. 2012;11:839–849.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22148876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melo SA, Sugimoto H, O’Connell JT, Kato N, Villanueva A, Vidal A, Qiu L, Vitkin E, Perelman LT, Melo CA, Lucci A, Ivan C, Calin GA, Kalluri R. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell. 2014;26:707–721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4254633</ArticleId>
            <ArticleId IdType="pubmed">25446899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Camussi G, Deregibus MC, Bruno S, Grange C, Fonsato V, Tetta C. Exosome/microvesicle-mediated epigenetic reprogramming of cells. Am J Cancer Res. 2011;1:98–110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3180104</ArticleId>
            <ArticleId IdType="pubmed">21969178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, Lotze MT. Good things come in small packages: exosomes immunity and cancer. Cancer Gene Ther. 2014;21:139–141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24781373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol. 2009;9:581–593.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19498381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sprague DL, Elzey BD, Crist SA, Waldschmidt TJ, Jensen RJ, Ratliff TL. Platelet-mediated modulation of adaptive immunity: unique delivery of CD154 signal by platelet-derived membrane vesicles. Blood. 2008;111:5028–5036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2384131</ArticleId>
            <ArticleId IdType="pubmed">18198347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberson CD, Atay S, Gercel-Taylor C, Taylor DD. Tumor-derived exosomes as mediators of disease and potential diagnostic biomarkers. Cancer Biomark. 2010;8:281–291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22045359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang HG, Grizzle WE. Exosomes and cancer: a newly described pathway of immune suppression. Clin Cancer Res. 2011;17:959–964.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3155407</ArticleId>
            <ArticleId IdType="pubmed">21224375</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
